Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.39 |
| ▸ | JAK2 | O60674 | 6/20 | 0.39 |
| ▸ | AURKA | O14965 | 6/20 | 0.39 |
| ▸ | JAK1 | P23458 | 3/20 | 0.39 |
| ▸ | TYK2 | P29597 | 3/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298354 | 0.89 | AURKA (0.39) | JAK3JAK2AURKAJAK1TYK2 | |
| SCHEMBL1298571 | 0.88 | DHODH (0.36) | JAK3JAK2AURKALIMK1LIMK2 | |
| SCHEMBL1298249 | 0.87 | KMT2A (0.43) | JAK3JAK2AURKAAURKBPAK4 | |
| SCHEMBL1298355 | 0.87 | AURKA (0.37) | JAK3JAK2AURKAJAK1TYK2 | |
| SCHEMBL1298289 | 0.86 | DHODH (0.34) | AURKANTRK1AURKBDHODHPLK4 | |
| SCHEMBL1298489 | 0.86 | AURKA (0.39) | JAK3JAK2AURKAJAK1TYK2 | |
| SCHEMBL1299180 | 0.86 | JAK3 (0.41) | JAK3JAK2AURKANTRK1AURKB | |
| SCHEMBL1298787 | 0.85 | KDM4E (0.37) | JAK3JAK2AURKAJAK1TYK2 | |
| SCHEMBL1298579 | 0.84 | DHODH (0.40) | JAK3JAK2AURKAJAK1TYK2 | |
| SCHEMBL1299082 | 0.84 | DHODH (0.40) | JAK3JAK2AURKAJAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | claimed |
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | JAK3 3/4885JAK2 1/4885AURKA 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.